Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.90 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.90 |
| ▸ | BCHE | P06276 | 4/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.61 |
| ▸ | MGLL | Q99685 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9254006 | 0.98 | LTA4H (0.87) | LTA4HEPHX2BCHEFFAR1FFAR4 | |
| SCHEMBL10405807 | 0.98 | LTA4H (0.87) | LTA4HEPHX2BCHEFFAR1FFAR4 | |
| SCHEMBL7367359 | 0.98 | LTA4H (0.87) | LTA4HEPHX2BCHEFFAR1FFAR4 | |
| SCHEMBL8888466 | 0.98 | LTA4H (0.87) | LTA4HEPHX2BCHEFFAR1FFAR4 | |
| SCHEMBL1563277 | 0.95 | LTA4H (1.00) | LTA4HEPHX2BCHEFFAR1FFAR4 | |
| SCHEMBL11687518 | 0.93 | LTA4H (0.97) | LTA4HEPHX2BCHEFFAR1FFAR4 | |
| SCHEMBL14300868 | 0.90 | LTA4H (0.90) | LTA4HEPHX2BCHEFFAR1FFAR4 | |
| SCHEMBL12040562 | 0.89 | LTA4H (0.77) | LTA4HEPHX2BCHEFFAR1FFAR4 | |
| SCHEMBL12630258 | 0.89 | LTA4H (0.77) | LTA4HEPHX2BCHEFFAR1FFAR4 | |
| SCHEMBL5700 | 0.87 | LTA4H (0.80) | LTA4HEPHX2BCHEFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398168-B2 | Preparation method of a glycoside compound | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2025-08-26 | — | — | US | disclosed |
| CN-111961006-B | Method for synthesizing intermediate of trilithiotinib triazole | 同济大学 | 2023-03-28 | — | — | CN | disclosed |
| US-20220380399-A1 | PREPARATION METHOD OF A GLYCOSIDE COMPOUND | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2022-12-01 | — | — | US | disclosed |
| WO-2021139621-A1 | METHOD FOR PREPARING GLYCOSIDE COMPOUND | 上海和黄药业有限公司 | 2021-07-15 | — | — | WO | disclosed |
| CN-111961006-A | Method for synthesizing intermediate of trilithiotinib triazole | 同济大学 | 2020-11-20 | — | — | CN | disclosed |
| EP-1270571-B1 | Heterocyclic compounds, their production and use | TAKEDA PHARMACEUTICAL (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-7019172-B2 | Process for preparation of S-(-)-betaxolol and salts thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-03-28 | — | — | US | disclosed |
| US-20060004109-A1 | Cyclopropanating 1-(2-allyloxyethyl)-4-benzyloxybenzene by the Simmon-Smith reaction with Furukawa modification to obtain the enantiomer 1-benzyloxy-4-(2-cyclopropyl methoxyethyl)benzene of high purity; avoiding the use of highly lacrymatric and unstable cyclopropylmethyl halide | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-01-05 | — | — | US | disclosed |
| US-20040138160-A1 | Preventive/therapeutic method for cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040116330-A1 | Diagnosing or specifying a growth factor receptor expressed in cancer cells, and selectively inhibiting all or a part of the growth factor receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-0512065-A4 | APPARATUS AND METHOD FOR IONTOPHORETIC TRANSFER | — | 1992-12-30 | — | — | EP | disclosed |
| EP-0512065-A1 | APPARATUS AND METHOD FOR IONTOPHORETIC TRANSFER | GENSIA PHARMACEUTICALS, INC. (US) | 1992-11-11 | — | — | EP | disclosed |
| US-5124070-A | High speed response | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-06-23 | — | — | US | disclosed |
| US-5108363-A | DIAGNOSIS, EVALUATION AND TREATMENT OF CORONARY ARTERY DISEASE BY EXERCISE SIMULATION USING CLOSED LOOP DRUG DELIVERY OF AN EXERCISE SIMULATING AGENT BETA AGONIST | GENSIA PHARMACEUTICALS, INC. (US) | 1992-04-28 | — | — | US | disclosed |
| US-5088978-A | APPARATUS AND METHOD FOR IONTOPHORETIC TRANSFER | GENSIA PHARMACEUTICALS, INC. (US) | 1992-02-18 | — | — | US | disclosed |
| WO-1991011215-A1 | APPARATUS AND METHOD FOR IONTOPHORETIC TRANSFER | GENSIA PHARMACEUTICALS, INC. (US) | 1991-08-08 | — | — | WO | disclosed |
| EP-0357372-A2 | Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-03-07 | — | — | EP | disclosed |
| EP-0329464-A2 | System for the closed-loop administration of an exercise simulating agent | GENSIA, INC. (US) | 1989-08-23 | — | — | EP | disclosed |
| US-4761420-A | CARDIOVASCULAR DISORDERS | LABORATOIRES SYNTEX S.A. (FR) | 1988-08-02 | — | — | US | disclosed |
| EP-0249245-A2 | Antihypertensive dihydropyridine derivatives | LABORATOIRES SYNTEX S.A. (FR) | 1987-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398168-B2 | Preparation method of a glycoside compound | GALE, ST6GAL1, MGAM | LTA4H 887/4885EPHX2 308/4885BCHE 344/4885 |
| US-20060004109-A1 | Cyclopropanating 1-(2-allyloxyethyl)-4-benzyloxybenzene by the Simmon-Smith reaction with Furukawa modification to obtain the enantiomer 1-benzyloxy-4-(2-cyclopropyl methoxyethyl)benzene of high purity; avoiding the use of highly lacrymatric and unstable cyclopropylmethyl halide | SMAD2, SPHK1, TGFBR1 | LTA4H 519/4885EPHX2 866/4885BCHE 2329/4885 |
| US-20220380399-A1 | PREPARATION METHOD OF A GLYCOSIDE COMPOUND | GALE, ST6GAL1, MGAM | LTA4H 887/4885EPHX2 308/4885BCHE 344/4885 |
| US-20040138160-A1 | Preventive/therapeutic method for cancer | EGFR, ERBB2, ERBB3 | LTA4H 3586/4885EPHX2 1905/4885BCHE 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.